Harvard Health Challenge Recognizes Home Health Tech Among Finalists

Among four finalists in Harvard University’s Acceleration Challenge, a home health tech company—the only home health company on the list—has made the cut.

Medalogix was recognized by the challenge for its Bridge solution; a technology that facilitates end of life care conversations with patients who would benefit from hospice care.

The challenge received applications from close to 500 different health care solutions and recognized the top four finalists with cash prices from Harvard Business School, the administrator of the challenge.

In addition to the prize, Medalogix will be the subject of an upcoming Harvard Business review case study, and will have the opportunity to compete a year from now for the ultimate prize of $50,000.

“Being chosen as one of the more impactful healthcare innovations by such a prestigious institution like Harvard is a great compliment to us and validating to our mission,” said Dan Hogan, Medalogix founder and CEO. “For years we’ve been working with our heads down to innovate and build meaningful technology that improves patient care. Harvard’s Health Acceleration Challenge is a big stage that will give us the platform to affect even more patients in the long run. Our team couldn’t be more thrilled.”

Written by Elizabeth Ecker

Elizabeth Ecker on EmailElizabeth Ecker on Linkedin
Elizabeth Ecker
Director of Content at Home Health Care News
Curious about all things, when not writing about senior housing topics, Liz is an avid explorer of food. She loves trying new recipes, new restaurants and new ice cream flavors. (Current favorite: Goat cheese with red cherries.)



By continuing to use the site, you agree to the use of cookies. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. For more information, see our cookie policy